BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amarantus Therapeutics to Present at the OneMedForum 2010 Conference


1/7/2010 11:05:26 AM

SUNNYVALE, CA--(Marketwire - January 07, 2010) -

Amarantus Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, today announced its participation in the OneMedForum 2010 Emerging Company Finance Conference on Tuesday, January 12, 2010. The conference is being held at the Sir Francis Drake Hotel in San Francisco. Martin D. Cleary, Chairman and CEO, will present an overview of Amarantus on Tuesday, January 12, 2010 at 2:25 p.m. PST.

For more information about this conference, please visit: http://www.onemedplace.com/onemedforum/

To listen to the audiocast of the presentation live or a replay of the event, please visit the company's web site at www.amarantustherapeutics.com

Amarantus Therapeutics, Inc. also announced that the company has appointed Vern Norviel, J.D. to the position of Corporate Secretary. Mr. Norviel is a partner at Wilson Sonsini Goodrich & Rosati, where he leads the firm's patents and innovation counseling practice. Joining the Board of Directors is Kenneth L. Coleman, Chairman of Accelrys, Inc., a leading software provider to the biotechnology industry, and Gene Mancino, a founding partner in Mancino Burfield Edgerton LLP., a life sciences executive search firm.

"We are pleased to welcome Kenneth, Gene and Vern to the Company at this critical stage in Amarantus Therapeutics' growth," said Mr. Cleary. "All three are highly respected in their sectors and strengthen our solid team, providing a good balance of scientific, business and legal experience."

Mr. Norviel previously served as general counsel and corporate secretary of Perlegen Sciences, Inc., senior vice president and general counsel at Affymetrix, Inc., and partner at Townsend & Townsend & Crew LLP in Palo Alto. Vern has more than two decades of experience in formulating successful strategies for life science companies and the development of their IP programs. During his career, he has authored or prosecuted more than 15 patents that have been litigated in the United States and abroad, and has overseen intellectual property lawsuits throughout the world.

Mr. Coleman is founder, former Chairman and CEO of ITM Software (sold to BMC Corp.). Previously, he was executive vice president of global sales, service and marketing for Silicon Graphics, Inc. and vice president of product development at Activision, Inc. Mr. Coleman currently serves on the boards of Accelrys, City National Bank, MIPS Technologies and United Online. He earned both a bachelors and a masters degree from The Ohio State University. He also served as a captain in the United States Air Force.

Mr. Mancino has been involved in the life sciences industry since 1979. He advises both development stage and fully integrated biopharmaceutical companies with respect to operational management, strategic leadership and corporate governance. He is currently a Business Advisor to Creative BioVentures LLC, a Board Member at Fish Nature, Inc, and Limited Partner at Mediphase Venture Partners and Taraval Associates LLC. Gene earned an AB degree from Princeton University.

About Amarantus Therapeutics, Inc.

Amarantus Therapeutics, Inc. is a privately held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including neurodegenerative and cardiovascular. Amarantus Therapeutics' most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinson's disease and Myocardial Infarction. Additional information is available at www.amarantustherapeutics.com.


CONTACTS:

Media:
Erik Clausen
Kena Hudson
College Hill, Inc.
415-230-5385
Erik.Clausen@CollegeHill.com
Kena.Hudson@CollegeHill.com

Investors:
Michael D. Becker
President & CEO
MD Becker Partners LLC
267-756-7094
Michael@mdbpartners.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES